Amphetamine Stimulant Prodrug denied as not FDA-approved for this use by Aetna?

Aetna's specific coverage criteria for amphetamine stimulant prodrug are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Issues a "Not FDA-Approved" Denial for Amphetamine Stimulant Prodrugs

This type of denial typically arises when Aetna's system flags that the prescribed use does not match what it has on file as the FDA-approved indication, or — less commonly — when an older formulary record has not been updated to reflect current FDA status. It can also occur when a medication is prescribed off-label for a condition beyond the approved indication, which is a distinct coverage question from whether the drug itself holds FDA approval.

## Why This Denial Is Appealable

If the prescription is for an FDA-approved indication, the denial is factually incorrect and should be overturned with minimal documentation. Pull the current FDA-approved prescribing information directly from the FDA's Drugs@FDA database, confirm the approved indication, and attach it to your appeal with a note from your prescriber confirming the prescribed use matches the label. If the use is off-label, the appeal pathway shifts: you will need to demonstrate that the off-label use is supported by published medical literature and recognized by an applicable professional-society guideline — and that Aetna's own policy does not categorically exclude it.

## Your Federal Appeal Rights

• Internal appeal: File within the deadline on your denial notice. Aetna must issue a decision within 30 days (pre-service) or 60 days (post-service).
• External review (ACA §2719 / ERISA §503): If the internal appeal is denied, request independent external review within four months. An IRO experienced in pharmaceutical coverage can evaluate whether the denial is medically and factually supported.
• Expedited track: Available for urgent clinical need.

## Documentation to Gather

1. Current FDA prescribing information — download directly from Drugs@FDA; highlight the approved indication and confirm it matches the diagnosis on your claim. 2. Prescriber attestation — a signed statement from your prescriber confirming the prescribed indication, tied to your documented diagnosis. 3. Diagnosis confirmation in the chart — the clinical note establishing the covered condition. 4. If off-label: Published guideline or peer-reviewed support from the relevant specialty society, plus a detailed medical-necessity letter.

## Criteria-Mapping Structure

Obtain Aetna's coverage criteria for this medication from their published medical policy library. Map your evidence:

| Denial Basis | Rebuttal Evidence | |---|---| | Drug not FDA-approved (if factually incorrect) | Current FDA prescribing label showing approved indication | | Use outside approved indication | Prescriber attestation + specialty-society guideline reference | | Plan policy exclusion | Identify applicable exception language in Aetna's policy |

A factual denial based on an incorrect FDA-approval assumption is one of the more straightforward categories to overturn. Move quickly, document clearly, and request expedited review if clinically appropriate.